completed

The objective of the MVP study was to determine:

  • If postoperative bridging therapy with full-dose heparin anticoagulation is superior to low-dose heparin bridging therapy in the immediate post-mechanical heart valve implantation period; and
  • Whether postoperative bridging therapy with LMWH is superior to UFH bridging therapy in the immediate post-mechanical heart valve implantation period.

MVP was a retrospective chart review of antithrombotic use over 30 days after valve surgery.

Primary endpoint:

To determine whether postoperative bridging therapy with full-dose heparin anticoagulation is superior to low-dose heparin bridging therapy in the immediate post-mechanical heart valve implantation period.

Secondary endpoint:

To determine whether postoperative bridging therapy with LMWH is superior to UFH bridging therapy in the immediate post-mechanical heart valve implantation period.

Study Type

Observational - Registry

Study Design

Retrospective chart review

NO. of Countries

1

NO. of Sites

5

NO. of Participants

1777

Study Period

2010 - 2013

Sponsor

PHRI

Back To Top